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CObjective: Fine-needle aspiration biopsy (FNAB) is a safe and inexpen-
sive diagnostic procedure for evaluating thyroid nodules.Up to 25% of
the results from an FNAB, however, may not be diagnostic or may be
indeterminate, leading to a subsequent diagnostic thyroid surgery. A
new molecularly based diagnostic test could potentially reduce inde-
terminate cytological results and, with high accuracy, provide a defin-
itive diagnosis for cancer in thyroid nodules. The aim of the study was
to estimate the cost-effectiveness of utilizing a molecular diagnostic
(DX) test as an adjunct to FNAB, compared with NoDX, to improve the
preoperative diagnosis of thyroid nodules. Methods: We constructed a
patient-level simulation model to estimate the clinical and economic
outcomes of using a DX test comparedwith current practice (NoDX) for
the diagnosis of thyroid nodules. By using a cost-effectiveness frame-
work, we measured incremental clinical benefits in terms of quality- O
urge
ty fo
http://dx.doi.org/10.1016/j.jval.2012.06.017djusted life-years and incremental costs over a 10-year time horizon.
esults: Assuming 95% sensitivity and specificity of the Dx test when
sed as an adjunct to FNAB, the utilization of the DX test resulted in a
ain of 0.046 quality-adjusted life-years (95% confidence interval 0.019–
.078) and a saving of $1087 (95% confidence interval $691–$1533) in
irect costs per patient. If the cost of the Dx test is less than $1087 per
est, we expect to save quality-adjusted life-years and reduce costs
hen it is utilized. Sensitivity of the DX test, comparedwith specificity,
ad a larger influence on the overall outcomes.
eywords: cost-effectiveness, gene expression, molecular diagnostic
est, thyroid cancer, fine needle aspiration biopsy, The Bethesta System
or Reporting Thyroid Cytopathology (TBSRTC).
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Thyroid nodules are common, affecting from4% to 7% in the general
population [1]. Fortunately, only a small proportion of these nodules
(approximately5%)arecancerous [1,2]. Fine-needleaspirationbiopsy
(FNAB) is currently the standard of practice for evaluating thyroid
nodulesdue to its lowcost, lowcomplication rate, andavailability [3].
The introduction of FNAB in the early 1980s has resulted in signifi-
cant economic savings and improved patient outcomes by reducing
the number of diagnostic thyroid operations required and improving
the detection rate of thyroid cancer [4].
A major drawback of FNAB of thyroid nodules is the large
umber of indeterminate or suspicious cancer diagnoses in that
ften the lesions cannot definitively be classified as benign or
alignant following FNAB. Clinical decision making following
n indeterminate cytological result is challenging and may lead
o either overtreatment or undertreatment of thyroid nodules.
his diagnostic uncertainty is a consequence of not only the
ubjective nature of thyroid cytology but also the overlapping
ytomorphologic characteristics of benign and malignant thy-
oid lesions. The Bethesda System for Reporting Thyroid Cyto-
athology (TBSRTC) is the result of a recent multidisciplinary
ffort to develop a uniform system for reporting thyroid FNAB
* Address correspondence to: Sam M. Wiseman, Department of S
Burrard Street, Vancouver, BC V6Z 1Y63, Canada.
E-mail: smwiseman@providencehealth.bc.ca.
1098-3015 – see front matter Copyright © 2012, International Socie
Published by Elsevier Inc.cytological results and their clinical significance [5]. The Be-
thesda thyroid FNAB cytology reporting system is particularly
helpful for providing a clear estimate of cancer risk and recom-
mendations for the management of indeterminate cases (i.e.,
atypia of undetermined significance, follicular neoplasm, and
suspicious cases). Even after following the currently recom-
mended diagnostic algorithm, about half of the thyroid nodules
operated on for an indeterminate diagnosis are eventually
found to be benign [5,6]. Therefore, the development of a new
diagnostic test that can serve as an adjunct to FNAB and reduce
the number of unnecessary diagnostic thyroid operations
would have significant clinical and economic value.
In the current study, we aimed to 1) evaluate the overall per-
formance of FNAB in combination with the TBSRTC (current prac-
tice) in directing thyroid nodule surgical management and 2) esti-
mate the cost-effectiveness of using a new molecular diagnostic
(DX) test as an adjunct to FNAB compared with best current prac-
tice (FNAB in combination with the TBSRTC guidelines, hereafter
referred to as NoDX). We performed the analyses in scenarios for
only individuals with an indeterminate FNAB cytological diagno-
sis, as well as for all individuals who present with thyroid nodules
(i.e., including nondiagnostic, benign, and malignant cases in the
target population).
ry, University of British Columbia, St. Paul’s Hospital, C303-1081
r Pharmacoeconomics and Outcomes Research (ISPOR).
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Model design
We developed a patient-level discrete event simulation model by
using Arena, Version 13.0 (Rockwell Software, Inc., Milwaukee, WI),
to calculate the incremental cost-effectivenessofusing theDX test in
conjunction with FNAB relative to current practice (NoDX) in two
simulated cohorts of 10,000 patients with an initial indeterminate
FNAB cytological diagnosis. In a patient-level model, one hypotheti-
cal patient is created and assigned to the NoDX arm and an identical
clone is created and assigned to the DX arm (see Figure 1 available in
the Appendix in Supplemental Material found at http://dx.doi.org/
10.1016/j.jval.2012.06.017). The model was run over a 10-year time
horizon, and results were determined from the societal perspective.
Depending on the subsequent diagnostic results in each arm, pa-
tients underwent either a total thyroidectomy or hemithyroidec-
tomy, or alternatively were followed clinically, in accordance with
the TBSRTC. In particular, we simulated the number of malignant
cases across diagnostic categories, and then by comparing the final
cytology andhistology, each patientwas classified as a true-positive,
false-positive, true-negative, or false-negative cancer case. The inci-
dence of major morbidity following surgery (i.e., permanent hypo-
parathyroidism and/or recurrent laryngeal nerve injury [RLNI]) and
cancer recurrence was included in the model as was cancer-related
mortality.
We needed to explicitly simulate the results of sequential test
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Fig. 1 – Incremental cost and effectiveness for different sens
adjusted life-year.outcomes for each patient to calculate the overall number of false epositives and false negatives in our simulation. We also modeled
the time as a continuous variable (rather than using fixed cycles).
As such, we used discrete event simulation, which offers the ca-
pacity to develop continuous time, patient-level simulations with
great flexibility for doing first-order and second-order sensitivity
analyses [7,8].
Data sources and assumptions
In the simulation, following the TBSRTC classification of a nodule,
therewere six possible cytologic outcomes subsequent to an FNAB
[5]: 1) nondiagnostic or unsatisfactory, 2) benign, 3) atypia or fol-
licular lesion of undetermined significance, 4) follicular neoplasm,
5) suspicious formalignancy, or 6) malignant. We defined an inde-
terminate cytological result as an FNAB diagnosis being atypia or
follicular lesion of undetermined significance, follicular neo-
plasm, or suspicious for malignancy. Furthermore, on the basis of
review of the literature, we utilized the proportion of patients in
each category, and the probabilities of malignancy for each cate-
gory, to inform the progression through the model (Table 1) [5].
he possible pathways in themodel were designed on the basis of
roposed management recommendations for each cytological di-
gnostic category [5].
Unlike the NoDx test arm, the diagnostic results in the DX test
rm were confined to two possible diagnoses: benign or malig-
ant. The overall prevalence of malignancy was assumed to be
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1007V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 0 5 – 1 0 1 3tivity and specificity of the DX test, possible cytological and histo-
logical outcomes were simulated in the DX test arm.
Data from National Cancer Institute’s Surveillance, Epidemiol-
ogy, and End Results were utilized to characterize the major types
of thyroidmalignancy as well as the proportions of different types
of cancer conditional on having a malignant nodule (Table 1) [9].
Because there are large differences in themean age of onset for the
different types of thyroid cancer (e.g., individuals diagnosed with
anaplastic carcinoma are, on average, more than 20 years older
than individuals diagnosed with papillary carcinoma), the ex-
pected life years lost vary widely across the different types of thy-
roid cancer (Table 2). These differences are captured in the simu-
ation as are the differences in the mortality rates associated with
ifferent thyroid cancers [10].
Permanent hypoparathyroidism and permanent RLNI were
onsidered to be the two major complications of thyroid surgery.
espite being uncommon events [14], the morbidity associated
ith these complications is generally chronic and thus impacts
linical outcomes and costs over a lifetime. In the model, we as-
umed that the failure to detect a malignancy delays necessary
urgeries by 28 months on average [13,15] and, therefore, in-
reases the risk of cancer recurrence (relative risk  2.28) and
Table 1 – Model assumptions about cytology results.
Parameter Point
estimate (%)
Proportion of cytology results, first FNAB*
Nondiagnostic (ND) 11
Benign 65
Atypia of undetermined
significance (AUS)
4.5
Follicular neoplasm (FN) 7.3
Suspicious for malignancy 7.2
Malignant 5
Probability of malignancy conditional on
cytology results
ND 2.5
Benign 1.5
AUS 10
FN 22.5
Suspicious for malignancy 67.5
Malignant 98.5
Proportion of second cytology results if AUS
Benign 61.5
AUS 20.0
FN 6.9
Suspicious for malignancy 6.8
Malignant 4.7
Proportion of second cytology results if ND
ND 36.0
Benign 49.2
FN 5.5
Suspicious for malignancy 5.5
Malignant 3.8
Proportion of malignancy types
Papillary 79.7
Follicular 12.1
Medullary 2.4
Hurthle cell 4.9
Anaplastic 0.9
* Point estimates represent the middle of the reported ranges in Ciba
reported ranges.cancer-related mortality (relative risk  2.11) [13]. (Quality of life
We included 10 health states in the model: perfect health, sur-
gery, pre–radioactive iodine ablation, post–radioactive iodine
ablation weeks 0 to 4, post–radioactive iodine ablation weeks 4
to 8, unilateral RLNI, bilateral RLNI, hypoparathyroidism, recur-
rence of differentiated carcinoma, and death (Table 3). A heath
tate utility value (six-dimensional health state short form [de-
ived from short form 36 health survey]) was assigned to each
ealth state to facilitate the calculation of quality-adjusted life-
ears (QALYs) as the final model outcome [20]. For each individ-
al in the model, QALYs were calculated by multiplying the
tility values of each health state with the time spent in that
ealth state throughout the model [16].
Mernagh et al. [20] used health-related quality-of-life data
using short form 36 health survey questionnaire) that had been
ollected during an international multicenter randomized clin-
cal trial with patients who received ablation treatment for their
hyroid cancer [21]. We used the six-dimensional health state
hort form (derived from short form 36 health survey) utilities
eported in Mernagh et al. that were derived from short form 36
ealth survey data in the hypothyroid arm of this clinical trial
Range Distribution
(, )
Reference
Cibas and Ali [5]
(2.0, 20.0) Beta (5, 42)
(60.0, 70.0) Beta (236, 127)
(3.0, 6.0) Beta (34, 729)
(6.6, 8.0) Beta (371, 4708)
(6.5, 7.9) Beta (371, 4783)
(3.0, 7.0) Beta (24, 450)
Cibas and Ali [5]
(1, 4) Beta (11, 422)
(0, 3) Beta (4, 258)
(5, 15) Beta (14, 129)
(15, 30) Beta (28, 95)
(60, 75) Beta (105, 50)
(97, 99) Beta (581, 9)
Cibas and Ali [5]
(55.4, 67.7) Beta (153, 96)
(18.0, 22.0) Beta (320, 1279)
(6.2, 7.6) Beta (372, 5014)
(6.1, 7.5) Beta (373, 5094)
(4.3, 5.2) Beta (381, 7668)
Cibas and Ali [5]
(32.4, 39.6) Beta (256, 454)
(44.3, 54.2) Beta (203, 209)
(5.0, 6.1) Beta (378, 6456)
(4.9, 6.0) Beta (378, 6556)
(3.4, 4.2) Beta (385, 9777)
Davies and Welch [9]
(76.8, 82.6) Beta (607, 155)
(9.7, 14.5) Beta (92, 669)
(1.3, 3.5) Beta (18, 743)
(3.3, 6.5) Beta (37, 724)
(0.2, 1.6) Beta (7, 754)
l. Parameters for beta distributions are calculated on the basis of thes et aN  30).
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Parameter Point
estimate
Range Distribution Reference
Conditional probability of mortality (%) Shaha [10]
Papillary 7 (6.3, 7.7) Beta (372, 4941)
Follicular 15 (13.5, 16.5) Beta (340, 1926)
Medullary 24 (21.6, 26.4) Beta (304, 962)
Hurthle cell 25 (22.5, 27.5) Beta (300, 899)
Anaplastic 86 (77.4, 94.6) Beta (55, 9)
Average age of patients (y)* Hundahl [11]
Papillary 47 (37.6, 56.4) Gamma (0.47, 100)
Follicular 50 (40.0, 60.0) Gamma (0.50,100)
Medullary 48 (38.4, 57.6) Gamma (0.48, 100)
Hurthle cell 49 (39.2, 58.8) Gamma (0.49, 100)
Anaplastic 70 (56.0, 84.0) Gamma (0.70, 100)
Time between diagnosis and death in cancer-related cases
High-risk malignancy (mo) 7 (4.0, 6.0) Gamma (0.07, 100) Shaha [10]
High-risk malignancy (y) 5 (5.6, 8.4) Gamma (0.05, 100) Shaha [10]
Probability of cancer recurrence (%)† 15.5 (8.3, 40.0) Beta (3, 17) Kebebew [12]
Effect of false-negative FNAB cytology on outcomes Sipos and Mazzaferri [13]
Average delay in diagnosis (mo) 28 (25.2, 30.8) Normal (28, 1.4)
Relative risk of mortality 2.17 (2.0, 2.4) Normal (2.17, 0.11)
Relative risk of long-term recurrence 2.28 (2.1, 2.5) Normal (2.28, 0.11)
Probability of major side effects following
thyroidectomy (%)
Rosato et al. [14]
Persistent hypoparathyroidism 1.7 (1.5, 1.9) Beta (393, 22735)
Permanent laryngeal recurrent nerve (LRN) injury 1 (0.9, 1.1) Beta (396, 39203)
* Estimated on the basis of the age distribution of the malignant cases in Hundahl et al. [11].
† Risk of recurrent cancer in 10-year follow-up.Table 3 – Utility weights and unit costs.
Parameter Point
estimate
Range Distribution for
PSA*
Reference
Unit costs (US $)
HT, direct costs $2390 ($1912, $2868) Gamma (23.9, 100) Soria-Aledo et al. [16]
HT, indirect costs† $288 ($230, $346) Gamma (2.9, 100) Soria-Aledo et al. [16]
TT, direct costs $3058 ($2446, $3670) Gamma (30.6, 100) Soria-Aledo et al. [16]
TT, indirect costs $418 ($334, $502) Gamma (4.2, 100) Soria-Aledo et al. [16]
Ablation, direct costs $3740 ($2992, $4488) Gamma (37.4, 100) Wang et al. [17]
Ablation, indirect costs $784 ($627, $941) Gamma (7.8, 100) Wang et al. [17]
Ultrasound-guided FNAB $412 ($330, $494) Gamma (4.1, 100) Khalid [18]
Follow-up, 5 y $1111 ($889, $1333) Gamma (11.1, 100) Shrime [19]
Utilities
Surgery 0.637 (0.57, 0.70) Beta (145, 82) Mernagh et al. [20]
Preablation 0.548 (0.49, 0.60) Beta (180, 149) Mernagh et al. [20]
Postablation 0–4 wk 0.637 (0.57, 0.70) Beta (145, 82) Mernagh et al. [20]
Postablation 4–8 wk 0.819 (0.74, 0.90) Beta (72, 16) Mernagh et al. [20]
Unilateral RLNI 0.627 (0.56, 0.69) Beta (149, 88) Kebebew [12]
Bilateral RLNI 0.205 (0.18, 0.23) Beta (318, 1232) Kebebew [12]
Hypoparathyroidism 0.778 (0.70, 0.86) Beta (88, 25) Kebebew [12]
Cancer recurrence 0.54 (0.49, 0.59) Beta (183, 153) Kebebew [12]
Well 1 – – Definition
Duration of health states (d)
Length of hospitalization for TT 4.2 (3.4, 5.0) Gamma (0.04, 100) Soria-Aledo et al. [16]
Length of hospitalization for HT 2.9 (2.3, 3.5) Gamma (0.03, 100) Soria-Aledo et al. [16]
Time between surgery and ablation 7 (5.6, 8.4) Gamma (0.07, 100) Mernagh et al. [20]
Postablation recovery period I 28 (22.4, 33.6) Gamma (0.28, 100) Mernagh et al. [20]
Postablation recovery period II 28 (22.4, 33.6) Gamma (0.28, 100) Mernagh et al. [20]
FNAB, fine-needle aspiration biopsy; HT, hemithyroidectomy; PSA, probabilistic sensitivity analysis; RLNI, recurrent laryngeal nerve injury; TT,
total thyroidectomy.
* Parameters for gamma and beta distributions were calculated by assuming an SD equivalent to 10% of point estimates.
† Indirect costs for TT and HT were calculated on the basis of lengths of hospitalizations and assuming an average income of $99 per day. Theaverage income has been based on men and women annual income and assuming that 12% of the patients were men.
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The model included the cost of the DX test, total thyroidectomy,
hemithyroidectomy, clinical follow-up (i.e., yearly physician visits
for 5 years), radioactive iodine ablation procedure, and FNAB (Ta-
ble 3). The cost of the DX test was assumed to include costs of all
elated procedures including pathology, physician time, and spec-
men transport and processing.
Direct costs for total thyroidectomy or hemithyroidectomy
in our study were based on the results from Soria-Aledo et al.
[16]. Indirect costs for total thyroidectomy or hemithyroidec-
tomy were calculated on the basis of average lengths of hospi-
talizations subsequent to those surgeries and assuming an av-
erage income of $99 per day. We calculated the average annual
income of men and women on the basis of US census data and
assuming that 12% of the patients were men [16]. Our estima-
tion of average income per day is also consistent with the find-
ings from other studies including Wang et al. [17]. Both direct
and indirect costs of ablation were based on estimations that
have been reported in Wang et al. [17].
Model outcomes
Simulated outcomes for each patient were recorded for the 10-
year time horizon of the model (e.g., initial and final cytology,
occurrence of cancer, type of cancer, hemithyroidectomy, total
thyroidectomy, completion thyroidectomy, complications, and
mortality). The health outcomes, in terms of QALYs and costs for
each patient, were also accumulated throughout themodel stages
over the 10-year time horizon. In the base-case analysis, only the
direct costs were included and both QALYs and costs were dis-
counted at 3% annually. Sensitivity analyses, however, were con-
ducted by including indirect costs, and by varying the annual dis-
count rate from 3% to 0%. Finally, the sensitivity, specificity,
positive predictive value (PPV), and negative predictive value
(NPV) of the NoDx strategy (FNAB in combination with the
TBSRTC) were also estimated and compared with the results of
other studies.
We considered the societal perspective in this analysis, and the
results were reported in US $, year 2011 values. All the unit costs
were inflated to 2011 values in the model by using the annual
changes in the consumer price index.
Univariate sensitivity analysis
In the base-case scenario, we generated 10,000 patients for each
strategy, with each patient undergoing 1,000 random walks in
order to minimize first-level uncertainty, resulting in 10,000,000
simulations per arm [22]. Univariate sensitivity analyses were
then conducted to evaluate the effect of varying the value of
model parameters over a viable range on the overall outcomes
of the model. For a given level of DX test sensitivity, we reran
the model by increasing the test specificity from 80% to 100% by
2.5% increments and compared the resulting incremental costs
and QALYs. We repeated the same analysis by holding specific-
ity constant and increasing sensitivity 2.5% at each step. We
also explored the benefits of expanding the target population of
the DX test to include all individuals who present with palpable
thyroid nodules.
Probabilistic sensitivity analysis
Values of the parameters in the base-case model are point esti-
mates drawn from various studies and are intrinsically uncer-
tain. To capture the effect of parameter uncertainty on the out-
comes, we conducted a probabilistic sensitivity analysis by
assigning probability distributions to all model parameters [23].Results
Results of base-case analysis
In the base-case analysis, among 10,000 simulated patients with
an indeterminate diagnosis in the NoDX test arm (current prac-
tice), 4,407 benign cases underwent unnecessary diagnostic sur-
gery (false positives) while 116 cancers were not diagnosed (false
negatives). In comparison, assuming a DX test sensitivity and
specificity of 95%, the number of unnecessary diagnostic thyroid
operations was reduced to 323 and 175 cancer cases were not di-
agnosed (Table 4). Not surprisingly, the substantial reduction in
the number of operations was also associated with a reduction in
Table 4 – Base-case results of DX use in indeterminate
cases only.
NoDX
(n  10,000)
DX
(n  10,000)
Final cytology (number of
cases)
Nondiagnostic or
unsatisfactory (ND)
0 0
Benign 1479 6182
Atypia of undetermined
significance (AUS)
454 0
Follicular neoplasm (FN) 3971 0
Suspicious for
malignancy
3987 0
Malignant 109 3818
Final histology (number of
cases)
True negative 1898 6007
True positive 3579 3495
False positive 4407 323
False negative 116 175
Performance measures
(probabilities)
Sensitivity 0.97 0.95
Specificity 0.30 0.95
Positive predictive value
(PPV)
0.45 0.92
Negative predictive value
(NPV)
0.94 0.97
Malignant cases (number
of cases)
Papillary carcinoma 2924 2936
Follicular carcinoma 503 414
Medullary carcinoma 172 195
Hurthle cell carcinoma 75 92
Anaplastic carcinoma 21 33
Major adverse events
(number of cases)
Persistent
hypoparathyroidism
129 68
Permanent laryngeal
recurrent nerve injury
89 29
Cancer-related mortality 391 393
Outcomes
QALY loss 0.306 0.266
Cost (excluding DX test
cost, US $)
4638 3558
Incremental QALY 0.040
Incremental cost (US $)* 1080
DX, diagnostic; QALY, quality-adjusted life-year.
* Negative cost indicates saving.
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1010 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 0 5 – 1 0 1 3surgical-related complications (Table 4). Specifically, in the NoDx
test arm, 129 patients experienced persistent hypoparathyroidism
compared with only 68 in the DX test arm. Overall, using the DX
test resulted in a gain of 0.046 (95% credible interval 0.019–0.078)
QALYs per patient over 10 years (or, 46 QALYs per 1000 patients
treated) with a cost saving of $1087 (95% credible interval $691–
$1533) in direct costs per patient. Thus, if the cost of the DX test is
less than $1087, the DX test strategy would result in QALYs gained
and lower costs relative to using the NoDX test strategy.
As expected, varying the sensitivity and specificity of the DX
test impacted the results (Fig. 1). Given a specificity of 95%, if the
sensitivity of Dx is 87.5% or less, the incremental QALYs associ-
ated with using the DX test strategy are negative, suggesting that
the DX test strategy is inferior to theNoDX test strategy in terms of
clinical outcomes. As shown in Figure 1, the incremental QALYs
gainedvarywidelyunderdifferent assumptionsabout the sensitivity
of the DX test strategy, while changes in specificity had a smaller
effect on the incremental QALYs. Inclusion of indirect costs that are
generally related to productivity loss during surgical procedures and
inpatient hospital stays increased the estimated savings attributable
to the DX test strategy to $1251 per patient in the base-case analysis.
Implementation of the DX test strategy was associated with a one-
time cost per patient that is part of the overall direct cost in the DX
test arm. Figure 2 shows the net monetary benefit of using different
costs for theDX test strategyunder the assumptions of the base-case
scenario and using an arbitrary value of $50,000 per QALY gained as
the threshold willingness to pay ().
When we simulated 10,000 patients with an indeterminate
NAB diagnosis in the NoDX testing strategy arm (current prac-
ice), 3,695 patients had cancer and 3,579 of thosewere assigned to
urgery (either hemithyroidectomy or total thyroidectomy). A to-
al of 4407 patients with benign thyroid nodules also, however,
ere assigned to receive a diagnostic operation. Thus, we con-
luded that for indeterminate cases, sensitivity, specificity, PPV,
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Fig. 2 – Net monetary benefit of DX test for different levels o
calculated on the basis of QALY − C, where  QALY and
relative to NoDX, respectively, and  is society’s willingness
be $50,000. DX, diagnostic; QALY, quality-adjusted life-yearndNPV of current practice (FNAB combinedwith the TBSRTC) are7%, 30%, 45%, and 94%, respectively. When we considered all
hyroid nodules, the sensitivity, specificity, PPV, and NPV were
4%, 84%, 49%, and 99%, respectively.
Sensitivity analyses
The results of the univariate sensitivity analyses suggest that
the cost of hemithyroidectomy, the discount rate, and the risk
of permanent hypoparathyroidism have significant effects on
the incremental net monetary benefit (Fig. 3). A higher proba-
bility of malignancy among individuals with a cytological diag-
nosis of suspicious for malignancy, follicular neoplasm, and
atypia or follicular lesion of undetermined significance was as-
sociated with a higher incremental net monetary benefit for the
DX testing strategy. The results of univariate sensitivity analy-
ses suggested that neither of these changes in the input param-
eters could alter the overall outcome that the DX test results in
QALYs gained at lower cost over a broad range of assumptions
about input parameters.
We repeated the simulation to include all individuals who
present with thyroid nodules. By analyzing the results for all indi-
viduals, we evaluated the scenario where the DX test can be con-
sistently used in conjunction with all FNABs. In addition to poten-
tially higher sensitivity and specificity, it is expected that the new
DX test requires a very small amount of cellular material relative
to FNAB cytology, and therefore a significant proportion of nondi-
agnostic casesmay be reclassified into other diagnostic categories
by using the DX test. Under this scenario, sensitivity and specific-
ity of the NoDX test strategy was estimated to be 94% and 84%,
respectively. Assuming that the DX test couldmaintain a sensitiv-
ity and specificity of 95% in this scenario, it resulted in 0.025QALYs
gained (i.e., 25 per 1000 patients assessed) at a cost of $291 less
than that in the NoDx strategy (see Table 1 available in the Appen-
dix in Supplemental Materials found at http://dx.doi.org/10.1016/
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gest a high probability that the DX test is the dominant strategy
(see Figure 2 available in the Appendix in Supplemental Mate-
rial found at http://dx.doi.org/10.1016/j.jval.2012.06.017). All
imulated points fall in the southeast quadrant (the DX testing
trategy being more effective but less costly than the NoDx test
trategy) if the cost of the Dx test was less than $500. Therefore,
ssuming 95% sensitivity and specificity, a DX test strategy that
osts less than $500 is the dominant strategy with 100% cer-
ainty.
Discussion
The current study is the first to evaluate the incremental cost-
effectiveness of utilizing amolecular diagnostic testing strategy
relative to the currently recommended diagnostic strategy for
the diagnosis of thyroid cancer, and it is the first study to eval-
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Fig. 3 – Results of univariate sensitivity analysis. AUS, atypi
diagnosis; FN, follicular neoplasm; prob, probability; RLNI, ruate the overall performance of FNAB in combination with theTBSRTC. Given a 95% sensitivity and specificity, the utilization
of the DX test strategy to improve the preoperative diagnosis of
indeterminate thyroid nodules can substantially reduce the
number of diagnostic operations and result in considerable
QALY gains and cost savings. The potential cost savings are
inversely related to the cost of the DX test strategy but remain
beneficial if the cost of the Dx test is less than $1087. Provided
that the sensitivities of the DX test and NoDX test strategies are
comparable, the DX test strategy remains cost saving if the
specificity of the Dx test is more than 80%. In contrast, a small
decrement in the sensitivity of the DX test results in a larger
negative effect on incremental QALYs gained, because FNAB in
conjunction with the TBSRTC already provides high sensitivity
at the expense of very low specificity for indeterminate cases
and the negative clinical consequences of missing a malignant
case are much greater than the expected consequences associ-
ated with an unnecessary diagnostic operation for a benign
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dures following a false-positive cancer diagnosis that currently
comprise approximately half of all thyroid operations [5].
In this analysis, we compared the overall performance of the
DX test strategy with that of the NoDX test strategy in terms of
the number of undetected cancer cases and the number of pa-
tients with benign nodules who were assigned to undergo a
thyroid operation. We defined positive cancer diagnosis as a
patient who has been referred for consideration of surgery on
the basis of the overall evaluation of the diagnostic strategy, as
we believe that this definition is more clinically relevant. There-
fore, the estimated sensitivity, specificity, PPV, and NPV reflect
the overall ability of the strategy to identify cancer cases that
require surgery with a high degree of accuracy. For example, the
reported sensitivity for the NoDX test strategy reflects charac-
teristics of FNAB in combination with TBSRTC rather than FNAB
alone.
Previous studies have evaluated the performance of FNAB
alone for the diagnosis of thyroid nodules. Gharib and Goellner
[24] suggested that depending on the definition of cytological
outcomes, the sensitivity of FNAB can range from 65% to 98%
and the specificity can range from 72% to 100%. In a retrospec-
tive analysis of 37,895 cases reported by Ravetto et al. [25], the
sensitivity and specificity of FNAB was estimated to be 91.8%
and 75.5%, respectively. In a review by Tee et al. [26], the ob-
erved sensitivity and specificity of FNAB that has been re-
orted also has a broad range, suggesting that the estimated
haracteristics of FNAB depend on the criteria and the method
f measurement. Similar findings have also been reported by
everal other studies [6,27–30]. We believe that using different
ssumptions for assigning indeterminate cases into possible
iagnostic outcomes has contributed to having wide variation
cross those studies. In contrast, we have used referral (no re-
erral) to surgery as the criteria for defining positive (negative)
iagnosis. Furthermore, in this study, we have estimated char-
cteristics of FNAB in combination with TBSRTC rather than
NAB alone.
We have included the effect of cancer-related mortality on
ALYs, but the costs that can occur in final stages of cancer (e.g.,
alliative care) have not been accounted for in the model. The
umber of individuals who develop end-stage thyroid cancer,
owever, was virtually identical in both arms of the model, and
herefore would have limited impact on incremental costs or
utcomes. The impact of surgery on QALYs was calculated only
or the inpatient periods after surgery. In reality, discomfort and
imitation in daily activities usually lasts for a period of time
fter discharge from the hospital, and therefore the impact of
urgery on QALYs is likely underestimated in this model. Thus,
iven a higher frequency of surgeries in the NoDX test strategy,
his assumption slightly favored the NoDX test strategy.
Overall, the DX test strategy appears to be the dominant
iagnostic strategy, resulting in QALYs gained and reduced
osts compared with current practice, if it is shown to have a
igh sensitivity and specificity with a reasonable cost per test.
egardless of whether the Dx test strategy is based on gene
xpression, protein expression, transcription analysis, immu-
ocytochemistry, or some other type of molecular study, its
ltimate benefit is primarily due to its ability to reduce the num-
er of diagnostic operations performed for benign pathology in
ndividuals who present with thyroid nodules by more accu-
ately diagnosing thyroid cancer without the need for surgery.
or clinical relevance and applicability, future studies evaluat-
ng molecular diagnostic tests for thyroid cancer must take eco-
omic considerations into account.
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